Raymond James Financial Inc Lineage Cell Therapeutics, Inc. Transaction History
Raymond James Financial Inc
- $264 Billion
- Q4 2024
A detailed history of Raymond James Financial Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 34,371 shares of LCTX stock, worth $23,715. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,371Holding current value
$23,715% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
126Shares Held
95.6MCall Options Held
63.8KPut Options Held
1K-
Broadwood Capital Inc New York, NY41.7MShares$28.7 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$6.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.6MShares$5.93 Million0.0% of portfolio
-
Defender Capital, Llc.5.96MShares$4.11 Million1.17% of portfolio
-
Logos Global Management LP San Francisco, CA5MShares$3.45 Million0.6% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $117M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...